Chinese gene synthesis firm Tsingke Biotechnology has bagged 400 million yuan ($57.2 million) in a Series B round led by Fortune Capital as well as Henan CICC Huirong Fund Management, a fund jointly set up by Henan Investment Group and CICC Capital.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
